These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
622 related articles for article (PubMed ID: 25176439)
1. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439 [TBL] [Abstract][Full Text] [Related]
2. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease. Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127 [TBL] [Abstract][Full Text] [Related]
3. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858 [TBL] [Abstract][Full Text] [Related]
4. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Hoops S; Nazem S; Siderowf AD; Duda JE; Xie SX; Stern MB; Weintraub D Neurology; 2009 Nov; 73(21):1738-45. PubMed ID: 19933974 [TBL] [Abstract][Full Text] [Related]
5. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Zadikoff C; Fox SH; Tang-Wai DF; Thomsen T; de Bie RM; Wadia P; Miyasaki J; Duff-Canning S; Lang AE; Marras C Mov Disord; 2008 Jan; 23(2):297-9. PubMed ID: 18044697 [TBL] [Abstract][Full Text] [Related]
6. The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. Pirogovsky E; Schiehser DM; Litvan I; Obtera KM; Burke MM; Lessig SL; Song DD; Liu L; Filoteo JV Parkinsonism Relat Disord; 2014 Jun; 20(6):627-31. PubMed ID: 24709086 [TBL] [Abstract][Full Text] [Related]
7. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Fujiwara Y; Suzuki H; Yasunaga M; Sugiyama M; Ijuin M; Sakuma N; Inagaki H; Iwasa H; Ura C; Yatomi N; Ishii K; Tokumaru AM; Homma A; Nasreddine Z; Shinkai S Geriatr Gerontol Int; 2010 Jul; 10(3):225-32. PubMed ID: 20141536 [TBL] [Abstract][Full Text] [Related]
8. Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. Sulzer P; Becker S; Maetzler W; Kalbe E; van Nueten L; Timmers M; Machetanz G; Streffer J; Salvadore G; Scholz E; Tkaczynska Z; Brockmann K; Berg D; Liepelt-Scarfone I J Neurol; 2018 Sep; 265(9):1976-1984. PubMed ID: 29936665 [TBL] [Abstract][Full Text] [Related]
9. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. Isella V; Mapelli C; Morielli N; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Picchi L; Napolitano A; Vista M; Appollonio IM Parkinsonism Relat Disord; 2013 Dec; 19(12):1160-3. PubMed ID: 24011719 [TBL] [Abstract][Full Text] [Related]
11. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting. Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705 [TBL] [Abstract][Full Text] [Related]
12. Changes on brief cognitive instruments over time in Parkinson's disease. Lessig S; Nie D; Xu R; Corey-Bloom J Mov Disord; 2012 Aug; 27(9):1125-8. PubMed ID: 22692724 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's disease. Gasca-Salas C; Estanga A; Clavero P; Aguilar-Palacio I; González-Redondo R; Obeso JA; Rodríguez-Oroz MC J Parkinsons Dis; 2014; 4(4):677-86. PubMed ID: 25208730 [TBL] [Abstract][Full Text] [Related]
14. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease. Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715 [TBL] [Abstract][Full Text] [Related]
15. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease. Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505 [TBL] [Abstract][Full Text] [Related]
16. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Memória CM; Yassuda MS; Nakano EY; Forlenza OV Int J Geriatr Psychiatry; 2013 Jan; 28(1):34-40. PubMed ID: 22368034 [TBL] [Abstract][Full Text] [Related]